Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR3 | P49019 | 5/20 | 0.63 |
| ▸ | RAB9A | P51151 | 5/20 | 0.45 |
| ▸ | NPC1 | O15118 | 4/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | SLC9A1 | P19634 | 2/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31473688 | 0.88 | HCAR3 (0.52) | HCAR3RAB9ANPC1MEN1KMT2A | |
| SCHEMBL20529672 | 0.88 | HCAR3 (0.52) | HCAR3RAB9ANPC1MEN1KMT2A | |
| SCHEMBL13201432 | 0.84 | HCAR3 (0.46) | HCAR3RAB9ANPC1PTGER4POLB | |
| SCHEMBL21463379 | 0.81 | HCAR3 (0.43) | HCAR3RAB9ANPC1MEN1KMT2A | |
| SCHEMBL24483865 | 0.80 | HCAR3 (0.46) | HCAR3RAB9ANPC1MEN1KMT2A | |
| SCHEMBL31473938 | 0.79 | HCAR3 (0.44) | HCAR3RAB9ANPC1MEN1KMT2A | |
| SCHEMBL27037509 | 0.79 | HCAR3 (0.44) | HCAR3RAB9ANPC1MEN1KMT2A | |
| SCHEMBL23119707 | 0.79 | HCAR3 (0.58) | HCAR3RAB9ANPC1POLBSLC9A1 | |
| SCHEMBL14722565 | 0.78 | RAB9A (0.68) | HCAR3RAB9ANPC1MEN1KMT2A | |
| SCHEMBL6044486 | 0.77 | HCAR3 (1.00) | HCAR3PTGER4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11802120-B2 | Fused cyclic urea derivatives as CRHR2 antagonist | RAQUALIA PHARMA INC. (JP) | 2023-10-31 | — | — | US | disclosed |
| US-11802120-B2 | Fused cyclic urea derivatives as CRHR2 antagonist | RAQUALIA PHARMA INC. (JP) | 2023-10-31 | — | — | US | disclosed |
| US-20210078975-A1 | FUSED CYCLIC UREA DERIVATIVES AS CRHR2 ANTAGONIST | RAQUALIA PHARMA INC. (JP) | 2021-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210078975-A1 | FUSED CYCLIC UREA DERIVATIVES AS CRHR2 ANTAGONIST | CRHR2, CRHR1, CRH | HCAR3 89/4885RAB9A 2868/4885NPC1 2391/4885 |
| US-11802120-B2 | Fused cyclic urea derivatives as CRHR2 antagonist | CRHR2, CRHR1, CRH | HCAR3 89/4885RAB9A 2868/4885NPC1 2391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.